Still, the company said other bamlanivimab studies continue and that it "remains confident that bamlanivimab monotherapy may prevent progression of disease for those earlier in the course of Covid-19."
It's testing bamlanivimab, alone or in combination with other drugs, in outpatients with mild-to-moderate Covid-19 and also in residents and staff at long-term care facilities.
The company continues testing of other possible Covid-19 treatments. Eli Lilly said it expects full-year Covid-19 research and development expenses of $400 million.